Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
Key PointsRegeneron’s leading weight-loss candidate could offer patients an option with fewer side effects.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.